知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

1607 records (took 0.052 seconds)

    Method for the preparation of isolated cell cultures, culture meidum for the cultivation of cell cultures, and cell cultures
    1.
    发明申请
    Method for the preparation of isolated cell cultures, culture meidum for the cultivation of cell cultures, and cell cultures 审中-公开
    分离细胞培养物的制备方法，培养细胞培养细胞培养物和细胞培养物

    公开(公告)号：US20040265996A1

    公开(公告)日：2004-12-30

    申请号：US10484305

    申请日：2004-06-02

    Inventor： Johannes Schwarz ,  Sigrid Schwarz

    IPC: C12N005/08

    CPC classification number: C12N5/0623 ,  C12N2501/58 ,  C12N2501/585

    Abstract: The invention describes a novel method for cultivating cell cultures comprising a plurality of progenitor cells, wherein the method comprises one or several steps selected from the group of expansion of the progenitor cells and modification of the progenitor cells of the cell culture in a culture medium. To ensure a rapid and continuous cultivation of these particular cells, it is suggested to use a cell culture provided essentially in the form of single cells and/or agglomerates with weak cell-cell interactions caused by the external influence of the culture medium leaving the majority of progenitor cells remains intact when the agglomerates are to be converted/transformed into single cells. Preferably the expansion and/or modification of the progenitor cells occurs under cell culture conditions which block at least partially the cellular receptors responsible for intercellular adhesion. The culture medium can comprise a Ca2null concentration of null0.5 mmol/l and/or inhibitors, important for cell-cell interactions of cell specific membrane bound receptors.

    Notch
    5.
    发明申请
    Notch 失效
    缺口

    公开(公告)号：US20040241180A1

    公开(公告)日：2004-12-02

    申请号：US10877563

    申请日：2004-06-25

    Inventor： Jonathan Robert Lamb ,  Margaret Jane Dallman ,  Gerard Francis Hoyne

    IPC: A61K039/00 ,  C12P021/06 ,  C07K014/705 ,  C12N005/08

    CPC classification number: C07K14/705 ,  A61K38/00 ,  A61K2039/5154 ,  C07K2319/00 ,  C12N2799/027 ,  G01N33/505 ,  Y02A50/412 ,  Y10S424/81

    Abstract: The present invention relates to the use of therapeutic compounds in the modification of T-cell, T-cell-antigen presenting cell (APC) interactions and the interactions between pathogenic organisms and immunocompetent cells of a host. In particular it relates to the use of these compounds in the modulation of the interaction between Notch proteins and their ligands and to the use of such compounds in the therapy of conditions such as graft rejection, autoimmunity, allergy, and asthma and infectious diseases.

    Abstract translation: 本发明涉及治疗性化合物在T细胞，T细胞抗原呈递细胞（APC）相互作用的修饰中的应用以及宿主的病原体和免疫活性细胞之间的相互作用。 特别地，它涉及这些化合物在调节Notch蛋白质及其配体之间的相互作用以及在治疗诸如移植排斥反应，自身免疫，变态反应，哮喘和感染性疾病等病症中的用途。

    Methods of generating human cd4+ th1 cells
    7.
    发明申请
    Methods of generating human cd4+ th1 cells 审中-公开
    产生人类cd4 + th1细胞的方法

    公开(公告)号：US20040241153A1

    公开(公告)日：2004-12-02

    申请号：US10488196

    申请日：2004-02-27

    Inventor： Daniel H. Fowler ,  Jeanne Hou ,  Unsu Jung ,  Ronald E. Gress ,  Bruce Levine ,  Carl June

    IPC: A61K045/00 ,  C12N005/08

    CPC classification number: C12N5/0636 ,  A61K2035/124 ,  A61K2039/515 ,  A61K2039/57 ,  C12N2501/23 ,  C12N2501/24 ,  C12N2501/515

    Abstract: Methods are provided for producing a population of substantially purified CD4null Th1 lymphocytes. The method includes stimulating a population of substantially purified CD4null T cells isolated from a subject by contacting the population with an anti-CD3 monoclonal antibody and an antibody that specifically binds to a T cell costimulatory molecule in the presence of a Th1 supportive environment to form a stimulated population of T cells. The stimulated population of CD4null T cells is allowed to proliferate in a Th1 supportive environment. In one example, the Th1 supportive environment includes at least 20 IU/ml of IL-2, for example about 1000 I.U./ml of IL-2, and a neutralizing amount of an IL-4, an IL-13, and/or an IL-4/IL-13 neutralizing agent. In other examples, the supportive environment further includes at least 1 ng/ml of IL-12, for example about 2.5 ng/ml of IL-12. Purified populations of Th1 cells are disclosed herein, as are methods for their use.

    Abstract translation: 提供了用于产生基本纯化的CD4 + Th1淋巴细胞群体的方法。 该方法包括通过使人群与抗CD3单克隆抗体和在Th1支持环境的存在下特异性结合T细胞共刺激分子的抗体来刺激从受试者分离的基本纯化的CD4 + T细胞群体，以形成 刺激的T细胞群体。 受激的CD4 + T细胞群在Th1支持环境中被允许增殖。 在一个实例中，Th1支持环境包括至少20IU / ml的IL-2，例如约1000IU / ml的IL-2，和中和量的IL-4，IL-13和/或 IL-4 / IL-13中和剂。 在其它实例中，支持性环境还包括至少1ng / ml的IL-12，例如约2.5ng / ml的IL-12。 本文公开了纯化的Th1细胞群体，以及它们使用的方法。

    Method of preparing immunoregulatory dendritic cells and the use thereof
    8.
    发明申请
    Method of preparing immunoregulatory dendritic cells and the use thereof 审中-公开
    免疫调节性树突状细胞的制备方法及其用途

    公开(公告)号：US20040235162A1

    公开(公告)日：2004-11-25

    申请号：US10740834

    申请日：2003-12-22

    Applicant: KIRIN BEER KABUSHIKI KAISHA ,  Katsuaki SATO

    Inventor： Katsuaki Sato

    IPC: C12N005/08

    CPC classification number: C12N5/064 ,  A61K2035/122 ,  A61K2035/124 ,  C12N2501/15 ,  C12N2501/23

    Abstract: This invention provides: a therapeutic agent for graft rejection, graft-versus-host disease, autoimmune disease, allergic disease, or other diseases comprising dendritic cells (DCs) induced under culture conditions comprising both IL-10 and TGF-null or DCs prepared by adding inflammatory stimulation (e.g., TNF-null or LPS) to the aforementioned DCs and, if necessary, an antigen associated with a target disease; a method of inducing human immunoregulatory dendritic cells by culturing human dendritic cells or their precursor cells in vitro with cytokines comprising at least IL-10 and TGF-null; human immunoregulatory dendritic cells obtained by such method; and a pharmaceutical composition comprising such human immunoregulatory dendritic cells.

    Abstract translation: 本发明提供：用于移植排斥，移植物抗宿主病，自身免疫性疾病，过敏性疾病或包括在包含IL-10和TGF-β或DC的培养条件下诱导的树突细胞（DC）的其它疾病的治疗剂，所述培养条件由 向上述DC加入炎症刺激（如TNF-α或LPS），如有必要，加入与目标疾病相关的抗原; 通过在体外用包含至少IL-10和TGF-β的细胞因子培养人树突状细胞或其前体细胞来诱导人免疫调节性树突状细胞的方法; 通过这种方法获得的人免疫调节性树突状细胞; 和包含这种人免疫调节性树突状细胞的药物组合物。

    Composition for the delivery of live cells and methods of use thereof
    9.
    发明申请
    Composition for the delivery of live cells and methods of use thereof 审中-公开
    用于递送活细胞的组合物及其使用方法

    公开(公告)号：US20040234547A1

    公开(公告)日：2004-11-25

    申请号：US10784908

    申请日：2004-02-23

    Applicant: Alkermes Controlled Therapeutics, Inc. ,  University of Massachusetts

    Inventor： Henry R. Costantino ,  Lawrence J. Bonassar ,  Mark A. Tracy

    IPC: A61K039/00 ,  A61F002/00 ,  C12N005/08

    CPC classification number: A61K35/32 ,  A61K35/30 ,  A61K35/39 ,  C12N5/0655 ,  C12N2531/00 ,  C12N2533/40

    Abstract: The invention relates to an improved method for administering live cells to a patient and compositions useful in the method. The composition comprises live cells and biocompatible, biodegradable polymer microparticles. The cells and microparticles of the cell/microparticle composition can be contacted immediately prior to administration, or can be contacted in culture for a specified period of time prior to administration. In the method of the invention, an effective amount of the cell/microparticle composition is administered to a patient in need thereof by injection to a treatment site of the patient to provide a therapeutic effect in the patient. The therapeutic effect can be, for example, the formation of new tissue at the treatment site, or the production and secretion of a biologically active secretory molecule at the treatment site. The therapeutic effect resulting from injection of the cell/microparticle composition into a treatment site, is determined by the type of cell present in the composition. The composition comprising lives cells and biocompatible, biodegradable polymer microparticles can further comprise a biologically active agent. In a preferred embodiment, the biologically active agent is incorporated into the microparticle. The biologically active agent can be, for example, factors which modulate cell growth.

    Abstract translation: 本发明涉及向患者施用活细胞的改进方法和用于该方法的组合物。 该组合物包含活细胞和生物相容的可生物降解的聚合物微粒。 细胞/微粒组合物的细胞和微粒可以在给药前立即接触，或者可以在施用之前在培养中接触指定的时间段。 在本发明的方法中，将有效量的细胞/微粒组合物通过注射给患者的治疗部位给予有需要的患者，以在患者体内提供治疗效果。 治疗效果可以是例如在治疗部位形成新组织，或者在治疗部位生产和分泌生物活性分泌分子。 将细胞/微粒组合物注入治疗部位所产生的治疗效果由组合物中存在的细胞类型决定。 包含生命细胞和生物相容的可生物降解的聚合物微粒的组合物可进一步包含生物活性剂。 在优选的实施方案中，将生物活性剂掺入微粒中。 生物活性剂可以是例如调节细胞生长的因子。

    Culture medium for long-term culture of hepatocytes
    10.
    发明申请
    Culture medium for long-term culture of hepatocytes 审中-公开
    长期培养肝细胞的培养基

    公开(公告)号：US20040229355A1

    公开(公告)日：2004-11-18

    申请号：US10437627

    申请日：2003-05-14

    Applicant: Board of Regents University of Texas System

    Inventor： Ming Chen ,  Iwona Stroynowski

    IPC: C12N005/08 ,  C12N005/02

    CPC classification number: C12N5/067 ,  C12N2500/25 ,  C12N2500/38 ,  C12N2501/11 ,  C12N2501/39

    Abstract: A culture medium, which is capable of sustaining long-term cultures of hepatocytes and liver cells. In this medium, mammalian primary hepatocytes retain highly replicative capacity and hepatic gene expression activity. The liver cells from genetically defined sources may be reproducibly immortalized without the delivery of foreign genes, such as viral oncogenes. The immortalized hepatocytes are non-tumorigenic, making them suitable for clinical and therapeutic purposes.

    Abstract translation: 一种能够维持肝细胞和肝细胞长期培养的培养基。 在该培养基中，哺乳动物原代肝细胞具有高度复制能力和肝基因表达活性。 来自遗传定义的来源的肝细胞可以可再现地永生化，而不会输送外源基因，如病毒癌基因。 永生化肝细胞是非致瘤性的，使其适合临床和治疗目的。

Patent Agency Ranking